



<b>Magellan Healthcare</b>	
<b>Clinical guideline:</b> <b>HYPERTHERMIA</b>	<b>Original Date:</b> November 2013 <b>Page 1 of 6</b>
<b>CPT Codes:</b> 77600, 77605, 77610, 77615, 77620	<b>Last Review Date:</b> July 2017
<b>Guideline Number:</b> NIA_CG_227	<b>Last Revised Date:</b> August 2016
<b>Responsible Department:</b> <b>Clinical Operations</b>	<b>Implementation Date:</b> January 2018

## INTRODUCTION

Hyperthermia is a treatment for cancer in which body tissue is exposed to high temperatures. Research has shown that hyperthermia can damage and kill cancer cells in some circumstances when it is used with radiation therapy. It is not approvable when used alone or in conjunction with chemotherapy.

The FDA has approved hyperthermia in combination with radiation therapy for the “palliative management of certain solid surface and subservice malignant tumors (i.e. melanoma, squamous or basal cell tumors, adenocarcinoma, or sarcoma) that are progressive or recurrent despite conventional radiation therapy“. The National Cancer Center Network recommends “that the use of hyperthermia be limited to treatment centers with appropriate training, expertise and equipment”.

Initial Clinical Reviewers (ICRs) and Physician Clinical Reviewers (PCRs) must be able to apply criteria based on individual needs and based on an assessment of the local delivery system.

## INDICATIONS FOR HYPERTHERMIA WITH RADIATION THERAPY

- Superficially recurrent melanoma
- Chest wall recurrence of breast cancer
- Recurrent cervical lymph nodes from head and neck cancer

## FREQUENCY OF PROCEDURE

A maximum of ten (10) hyperthermia treatments may be delivered two times per week at 7 hour intervals.

## CONTRAINDICATIONS FOR HYPERTHERMIA

- The use of intraluminal, endocavitary, interstitial, regional deep tissue hyperthermia exceeding 4 cm. in depth and whole body hyperthermia are considered *investigational*.
- There can not be any evidence of depth of tumor recurrence greater than 4 cm.
- There can be no evidence of metastatic disease for which systemic chemotherapy or hormonal therapy is planned or being given.

## ADDITIONAL INFORMATION:

**Local Hyperthermia** - Heat is applied to a small area only. Local hyperthermia is typically administered every 72 hours (i.e., twice a week) for a total of 10 to 12 treatments using applicators that are placed close to, or in, the tumor. Local hyperthermia can be administered using various techniques: external, intraluminal or endocavitary, and interstitial.

- **External Hyperthermia** - This technique is used for cancers that are on, or just below, the skin. The tumor is heated externally using applicators that are placed on, or near to, the affected area. Heat is then applied using high-frequency energy waves generated from a device outside the body (such as a microwave or ultrasound).
- **Intraluminal or Endocavitary Hyperthermia** - This technique may be used to treat cancers that are within or near to body cavities. A sterile probe that can be heated is placed inside the cavity where the tumor is. This heats the affected area.
- **Interstitial Hyperthermia** - This is used to treat tumors that are deep within the body. Under anesthetic, probes or wires are placed within the tumor tissue and then heated. This method allows tumors to be heated to a higher temperature than external techniques.

**Regional Hyperthermia** - Various approaches may be used to heat large areas of tissue, such as a body cavity, organ, or limb. This includes **all** of the following:

- **Deep Tissue** - This may be used to treat cancers within the body, such as cervical or bladder cancer. External applicators are positioned around the body cavity or organ to be treated, and microwave or radiofrequency energy is focused on the area to raise its temperature.
- **Regional perfusion** - In this procedure, some of the patient's blood is removed, heated, and then perfused back into the limb or organ.
- **Continuous hyperthermic peritoneal perfusion (CHPP)** - This is a technique used to treat cancers within the peritoneal cavity. During surgery, heated chemotherapy drugs flow from a warming device through the peritoneal cavity. The peritoneal cavity temperature reaches 106–108°F.

**Whole-body hyperthermia** - used to treat metastatic cancer. This can be accomplished by several techniques that raise the body temperature to 107–108°F, including the use of thermal chambers or hot water blankets.

### Additional Terminology:

Hyperthermia is also called thermal therapy or thermotherapy.

## REFERENCES

- American Cancer Society. Hyperthermia to Treat Cancer. Accessed May 16, 2016 from: <http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/hyperthermia>
- American College of Radiology (ACR)/American Society of Radiation Therapy (ASTRO) Coding Guide. Accessed October 14, 2015. <https://www.astro.org/Practice-Management/Radiation-Oncology-Coding/Index.aspx>
- American Society of Clinical Oncology. Using Hyperthermia for Cancer Treatment: Proofs, Promises, and Uncertainties. Accessed May 16, 2016 from: <http://www.ascopost.com/issues/january-15-2014/using-hyperthermia-for-cancer-treatment-proofs-promises-and-uncertainties/>
- BSD-2000 Brochure. Accessed October 14, 2015. [http://hyperthermia.pyrexar.com/acton/attachment/15060/f-0001/1/-/1-0001/1-0001:4a/bsd-2000\\_brochure.pdf](http://hyperthermia.pyrexar.com/acton/attachment/15060/f-0001/1/-/1-0001/1-0001:4a/bsd-2000_brochure.pdf)
- BSD-500 Brochure. Accessed October 14, 2015. [http://hyperthermia.pyrexar.com/acton/attachment/15060/f-0002/1/-/1-0001/1-0001:4a/bsd-500\\_brochure.pdf](http://hyperthermia.pyrexar.com/acton/attachment/15060/f-0002/1/-/1-0001/1-0001:4a/bsd-500_brochure.pdf)
- Conditions of Approval For An HDE. Department of Health and Human Services Letter. HUD and HDE for BSD-2000. Accessed October 14, 2015. [http://www.accessdata.fda.gov/cdrh\\_docs/pdf9/H090002a.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf9/H090002a.pdf)
- Dooley WC et al: Focused microwave thermotherapy for preoperative treatment of invasive breast cancer: a review of clinical studies. *Ann Surg Oncol*. 2010 Apr; 17(4):1076-93. Epub 2009 Dec 22.
- Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. *Journal of Clinical Oncology* 2003; 21(24):4560–4567.
- Gardner RA, et al: Focused microwave phased array thermotherapy for primary breast cancer. *Ann Surg Oncol*. 2002 May; 9(4):326-32.
- Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. *Critical Reviews in Oncology/Hematology* 2002; 43(1):33–56.
- Huilgol NG, Gupta S, Sridhar CR. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer: a report of randomized trial. *J Cancer Res Ther*. 2010 Oct-Dec;6(4):492-6.

Hyperthermia for Treatment of Cancer. National Coverage Determination (NCD) 110.1. Accessed October 14, 2015. <http://www.cms.gov/medicare-coverage-database/details/nccdetails.aspx>

Jones EL, Oleson JR, Prosnitz LR, Samulski TV, Vujaskovic Z, Yu D, Sanders LL, Dewhirst MW. Randomized trial of hyperthermia and radiation for superficial tumors. *J Clin Oncol*. 2005 May 1;23(13):3079-85.

Kiel KD, Refaat T, Navanandan N, et al. Breast Cancer - Local-Regional and Adjuvant Therapy. *J Clin Oncol*. 27:15s, 2009.

Linthorst M, van Rhoon GC, van Geel AN, et al. The tolerance of reirradiation and hyperthermia in breast cancer patients with reconstructions. *Int J Hyperthermia*. 2012;28(3):267-77.

Muller AC, Eckert F, Heinrich V, et al. Re-surgery and chest wall re-irradiation for recurrent breast cancer - a second curative approach. *BMC Cancer*. 2011 May 25;11(1):197.

National Cancer Institute. Hyperthermia in Cancer Treatment. Retrieved May 16, 2016 from: <http://www.cancer.gov/about-cancer/treatment/types/surgery/hyperthermia-fact-sheet>

National Comprehensive Cancer Network (NCCN). Breast Cancer Version 2.2016. Retrieved May 16, 2016 from: [https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf)

Oldenburg S. Elective re-irradiation and hyperthermia following resection of persistent locoregional recurrent breast cancer: A retrospective study. *Int J Hyperthermia*. 01-JAN-2010; 26(2): 136-44.

Overgaard J, Gonzalez Gonzalez D, Hulshof MC, et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. *Lancet*. 1995 Mar 4;345(8949):540-3. Accessed July 7, 2016 at: <http://www.ncbi.nlm.nih.gov/pubmed/7776772>

Singletary SE. Minimally invasive ablation techniques in breast cancer treatment. *Ann Surg Oncol*. 2002 May; 9(4):319-20.

van der Zee J. Heating the patient: a promising approach? *Annals of Oncology* 2002; 13(8):1173–1184.

Vargas HI et al: Focused microwave phased array thermotherapy for ablation of early-stage breast cancer: results of thermal dose escalation. *Ann Surg Oncol*. 2004 Feb; 11(2):139-46.

Vernon CC, Hand JW, Field SB, Machin D, Whaley JB, van der Zee J, van Putten WL, van Rhoon GC, van Dijk JD, González González D, Liu FF, Goodman P, Sherar M. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. *Int J Radiat Oncol Biol Phys*. 1996 Jul 1;35(4):731-44.

Vlastos G, Verkooijen HM. Minimally invasive approaches for diagnosis and treatment of early -stage breast cancer. *Oncologist* 2007; 12(1): 1-10.

Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, Felix R, Schlag PM. Hyperthermia in combined treatment of cancer. *Lancet Oncol*. 2002 Aug;3(8):487-97.

Zagar TM, Higgins KA, Miles EF, et al. Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy. *Radiother Oncol*. 2010 Dec;97(3):535-40.

Zhao Z, et al: Minimally-invasive thermal ablation of early-stage breast cancer: a systemic review. *Eur J Surg Oncol*. 2010 Dec; 36(12):1149-55. Review.

Reviewed/Approved by  Michael Pentecost, MD, Chief Medical Officer